These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6438835)

  • 1. Determination of tolrestat, a novel aldose reductase inhibitor, in serum and tissues.
    Hicks DR; Kraml M
    Ther Drug Monit; 1984; 6(3):328-33. PubMed ID: 6438835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
    Kemper C; Dvornik D
    Proc Soc Exp Biol Med; 1986 Sep; 182(4):505-10. PubMed ID: 3090558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
    Sestanj K; Bellini F; Fung S; Abraham N; Treasurywala A; Humber L; Simard-Duquesne N; Dvornik D
    J Med Chem; 1984 Mar; 27(3):255-6. PubMed ID: 6422042
    [No Abstract]   [Full Text] [Related]  

  • 5. High-performance liquid chromatographic analysis of glucose, fructose, sorbitol and low levels of the aldose reductase inhibitor sorbinil in human lens and plasma.
    Lloyd P; Crabbe MJ
    J Chromatogr; 1985 Oct; 343(2):402-6. PubMed ID: 3934205
    [No Abstract]   [Full Text] [Related]  

  • 6. Computer-assisted design and synthesis of novel aldose reductase inhibitors.
    Butera J; Bagli J; Doubleday W; Humber L; Treasurywala A; Loughney D; Sestanj K; Millen J; Sredy J
    J Med Chem; 1989 Apr; 32(4):757-65. PubMed ID: 2539477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
    Wrobel J; Millen J; Sredy J; Dietrich A; Kelly JM; Gorham BJ; Sestanj K
    J Med Chem; 1989 Nov; 32(11):2493-500. PubMed ID: 2509709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts.
    Müller P; Hockwin O; Ohrloff C
    Ophthalmic Res; 1985; 17(2):115-9. PubMed ID: 3920598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
    Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK
    Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of erythrocyte anion exchange by tolrestat, an inhibitor of aldose reductase.
    Gunn RB; Gunn HB
    Metabolism; 1989 Aug; 38(8):801-4. PubMed ID: 2503683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
    Stribling D; Mirrlees DJ; Harrison HE; Earl DC
    Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of AL01576 concentration in rat lenses and plasma by bioassay for aldose reductase activity measurements.
    Hockwin O; Müller P; Krolczyk J; McCue BA; Mayer PR
    Ophthalmic Res; 1989; 21(4):285-91. PubMed ID: 2511536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors.
    Srivastava SK; Petrash JM; Sadana IJ; Ansari NH; Partridge CA
    Curr Eye Res; 1982-1983; 2(6):407-10. PubMed ID: 6820339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [2,2',4,4'-tetrahydroxybenzophenone as a new aldose reductase inhibitor (author's transl)].
    Ono H; Hayano S
    Nippon Ganka Gakkai Zasshi; 1982; 86(4):353-7. PubMed ID: 6810663
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW; McNatt LG; Chandler ML; York BM
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of lens aldose reductase by Labiatae flavonoids.
    Tomás-Barberán FA; López-Gómez C; Villar A; Tomás-Lorente F
    Planta Med; 1986 Jun; (3):239-40. PubMed ID: 3092256
    [No Abstract]   [Full Text] [Related]  

  • 20. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
    Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
    J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.